AK104 - Chemotherapy

DRUG2 trials

Sponsors

Hunan Cancer Hospital, Xiangbo Wan

Conditions

Cervical Cancer Stage IVOvarian Cancer

Phase 2

AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

RecruitingNCT05430906

Hunan Cancer HospitalOvarian Cancer

Start: 2022-11-25End: 2026-01-31Target: 40Updated: 2023-04-25

A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer

RecruitingNCT06998394

Xiangbo WanCervical Cancer Stage IV

Start: 2025-03-12End: 2027-12-31Target: 30Updated: 2025-05-31

Related Papers

Abstract LB-B004: CD8+ Tumor-Infiltrating Lymphocytes and Systemic Immune-Inflammation Index revealed as a Predictor of Response to Neoadjuvant Cadonilimab Plus Chemotherapy in Advanced Ovarian Cancer from the Phase II CANECT Trial

Cancer Immunology Research2026-03-05

Patient with HR-proficient advanced ovarian cancer achieved a complete response with Cadonilimab combined chemotherapy (PD-1/CTLA-4 bispecific): a case report and literature review.

2025-06-15

An open, prospective, single arm, phase II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) with neoadjuvant chemotherapy in patients with advanced ovarian cancer: Interim analysis from the AK104-IIT-003 study.

Journal of Clinical Oncology2024-06-013 citations